Citation: Dahlström J, Zhang X, Ghaderi M, Hultcrantz M, Björkholm M, and Xu D. Dysregulation of shelterin factors coupled with telomere shortening in Philadelphia chromosome negative myeloproliferative neoplasms. Haematologica. 2015; 100:xxx doi:10.3324/haematol.2015.125765 Publisher's Disclaimer. Telomeres are nucleoprotein complexes mainly consisting of telomeric DNA and 6
Philadelphia chromosome negative myeloproliferative neoplasms (MPNs) are a group of clonal neoplastic diseases originating from the myeloid lineage. MPNs include polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). 1 Most MPNs are sporadic but familial clustering does occur. [1] [2] [3] The gain of function mutation of the JAK2 tyrosine kinase gene (JAK2
V617F
), a key disease driver, is seen in both sporadic and familial cases in roughly 95% of PV, 60% of ET and 50% of PMF patients, respectively. 3, 4 In addition, other oncogenic mutations and cytogenetic alterations are frequently observed in MPNs, suggesting a significant genomic instability. 4 An earlier report indicated that the JAK2 V617F mutation was responsible for these genetic alterations, while other studies demonstrated the same scenarios in cells without JAK2
. 3, 4 Taken together, it is probable that yet undiscovered common mechanisms exist, which trigger the genomic instability in
MPNs regardless of JAK2 status.
Telomeres are nucleoprotein complexes mainly consisting of telomeric DNA and 6
shelterin proteins (TRF1, TRF2, TPP1, POT1, TIN2 and RAP1) essential for chromosomeend protection. [5] [6] [7] Telomere dysfunction is an early event triggering genomic instability in tumorigenesis. 5 MPNs exhibit genetic alterations with an indolent clinical course. Earlier studies have shown shorter telomeres in leukocytes of patients with MPNs. 2, [9] [10] [11] However, it is currently unclear whether the shelterin protein expression is altered and associated with telomere shortening in MPNs. The present study was thus designed to address these issues.
We determined telomere length (TL), shelterin protein expression and telomerase activation in a cohort of 81 MPN patients and in 43 healthy adult controls. The characteristics of patients and healthy individuals are presented in table 1. As this group of disorders involve the myeloid lineage, we collected both peripheral blood granulocytes and lymphoid cells from patients and healthy controls, and determined TL in these cells using flow-FISH (Fig. 1A) (Supplementary methods). 10, 12 TL in granulocytes was significantly shorter in MPN patients than in healthy controls (mean ± SD, same below: 7.27 kb ± 2.11 vs 8.66 kb ± 1.82, P < 0.001, Fig. 1B ). As TL is highly age-dependent (r = -0.34, P <0.001, Fig. S1 ), we made a further comparison after correcting for the influence of age, in which the significant difference in TL between patients and healthy controls remained (P = 0.046). In contrast, there was no difference in TL of lymphoid cells between patients and healthy controls (8.38 kb ± 2.08 vs 8.67 kb ± 1.89, P = 0.437, Fig. 1C ). Furthermore, patients' granulocytes exhibited significantly shorter TL than that of their own lymphoid cells ( Fig. 1D , P = 0.001),
whereas TL did not differ between controls' granulocytes and lymphoid cells (8.66 kb ± 1.82 vs 8.67 kb ± 1.89, P = 0.976, Fig. 1E ). These results suggest that accelerated telomere attrition was restricted to myeloid cells of MPN patients, consistent with previous reports. 10, 11 To validate the TL assay using FLOW-FISH, we further employed a quantitative PCR We then determined whether the expression of shelterin factors was altered in patient granulocytes. mRNA levels of all 6 shelterin proteins were analyzed using qPCR ( Fig. 2) (Supplementary methods). There were no differences in TRF1 or TRF2 mRNA expression between healthy individuals and MPN patients (1.14 ± 1.62 vs 1.0 ± 1.27, P = 0.997 for TRF1, and 1.0 ± 0.43 vs 0.93 ± 0.26, P = 0.733 for TRF2). There was a higher expression of POT1 (1.54 ± 0.56 vs 1.0 ± 0.47, P <0.001) and TIN2 (1.20 ± 0.33 vs 1.0 ± 0.31, P <0.001) in MPN patients' granulocytes compared to that in healthy controls ( Fig. 2A and B) . When dividing patients into subtypes, POT1 expression remained significantly higher in all the 3 subtypes compared to healthy controls ( Fig. 2A and B, for comparison with ET, PV and PMF, P = 0.03, <0.001 and <0.001, respectively). TIN2 expression was significantly higher in PV and PMF patients (P <0.001 and 0.03, respectively), but not in patients with ET ( We observed that the JAK2 mutation was positively associated with POT1 expression, whereas it did not correlate with the expression of the other five shelterin proteins. POT1 mRNA levels were higher in patients carrying the JAK2 V617F mutation (P = 0.038, Fig. 2H ).
Furthermore, POT1 expression tended to correlate with JAK2 V617F allele burdens ( Fig. 2I , P = 0.08) based on the analysis of a limited patient number; this should be confirmed in a larger patient group. To determine whether the elevated POT1 expression was driven by the JAK2 V617F
, we performed experiments with a JAK2 inhibitor on the JAK2 V617F+/+ cell line HEL. Significantly diminished levels of POT1 mRNA were observed in HEL cells treated with LY2784544 (P = 0.001), accompanied by its protein downregulation ( Fig. 2J and K) . In contrast, LY2784544 did not inhibit POT1 expression in wt JAK2-carrying leukemic K562
cells.
The induction of telomerase reverse transcriptase (TERT) and activation of telomerase, an RNA-dependent DNA polymerase synthesizing telomeric DNA, are essential in malignant transformation, and whether this happens in MPNs with an indolent course is controversial. 13 We thus determined TERT mRNA levels using qPCR. There was no difference in TERT mRNA expression in granulocytes derived from MPN patients compared to those from healthy controls (1.29 ± 1.54 vs 1.0 ± 0.88, P = 0.35). Our finding suggests that telomerase remains silent in MPN cells.
In addition, KU80 is a DNA repair factor that has been shown to localize to telomeres, affect telomere length maintaining and prevent end joining. 14 We therefore determined its expression in patient granulocytes. KU80 mRNA expression was found to be significantly higher in granulocytes derived from patients with MPN than in those from healthy individuals (1.28 ± 0.31 vs 1.0 ± 0.28, P <0.001). KU80 mRNA levels were significantly positively correlated to TRF2, TPP1, POT1 and TIN2 expression, while negatively correlated to TL (data not shown). 
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Flow-FISH for TL analysis
Flow FISH of whole blood was performed as described in previous protocols with slight modifications. 1,2 Calf thymus cells were kindly donated from the butchery Ö-slakt AB (Värmdö, Stockholm) and prepared as previously described. where MESF is the fluorescent intensity given by QuickCal v.2.3, n base is the number of bases per PNA probe and n chr is the number of chromosomes in the specimen of origin of the cells.
Cell culture
The erythroleukemia cell line HEL (JAK2 V617F+/+ ) (DSMZ) was grown in RPMI 1640
complemented with 10% FBS, 1% L-glutamine and 1% penicillin-streptomycin (all from Gibco, Life Technologies). Cells were cultured in the presence of 3µM of the JAK2 V617F inhibitor LY2784544 (Sellek Chemicals) for 24 hrs and then harvested for POT1 mRNA and protein analysis.
RNA isolation and quantitative reverse transcription-PCR (qPCR)
Total cellular RNA in granulocytes from MPN patients and healthy controls was isolated using Trizol reagent (Life Technologies) and diluted to 100 ng/µl. Two µg RNA was used for reverse transcription using M-MLV (Life Technologies) according to the manufacturer's recommendation. Real time amplification was performed in triplicate using SYBR Green PCR Master Mix (Life Technologies) with QuantStudio 7 Flex Teal-Time PCR system (Applied biosystems). All primers were purchased from Invitrogen and their sequences are presented in table S1.
Protein expression analyses
Proteins were extracted from granulocytes of 9 patients and 9 healthy controls using Trizol 
JAK2 V617F allele burden analysis
The relative quantification of the JAK2 V617F c.1849G>T allele burden in DNA samples from 31 MPN patients was performed using duplicate qPCR. The common forward primer, the reverse primers for wild type and mutant type sequences and common probe are listed in Table S1 . The PCR amplification was run with primer concentrations at 300nmol/l and probe concentration at 200 nmol/l with an standard activation step of 10 min at 95°C, followed by 45 cycles of 15 s at 95°C and 60 s at 60°C on a ABI Prism7000 (Applied Biosystems, Foster City, CA, USA). The levels of the mutated JAK2 V617F allele burden in all samples was compared to the reference genomic DNA levels of the JAK2 V617F homozygous mutated DNA (HEL cells) diluted at tenfold with wildtype DNA.
Statistical analyses
All statistical analyses were made in Excel using 2-tailed Student's t-test for analysis of telomere length and expression of telomere binding proteins. For correlation analyses
Pearson's correlation coefficient was generated using the correlation tool in Excel's Analysis toolPak add-in software. A t-value was generated using the following formula;
The T-distribution calculation tool in Excel was then used to generate a p-value. For all calculations two tailed distribution was used. Age adjustment of telomere length was performed in the GraphPad prism 5 software using the ANCOVA-based function "compare slopes and intercepts". Target  Forward  Reverse  TRF1 5
Primers for telomere length 
